A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1

BACKGROUND: Abacavir/dolutegravir/lamivudine has been indicated in Korea since 2015 for treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of abacavir/dolutegravir...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sang-Kyu, Cho, Jung-Eun, Lee, Eun-Bin, Kim, Yeon-Sook, Jung, Sook-In
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551717/
https://www.ncbi.nlm.nih.gov/pubmed/37272234
http://dx.doi.org/10.3947/ic.2022.0176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551717/
https://www.ncbi.nlm.nih.gov/pubmed/37272234
http://dx.doi.org/10.3947/ic.2022.0176

Ejemplares similares